COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
Bedaquiline was recommended by WHO as the preferred option in treatment of MDR-TB patients with long regimen. However, no recommendation was given for the short MDR-TB regimen. Data from our small cohort of patients who switched injectable dug to bedaquiline suggest that bedaquiline based short regimen is effective and safe.